---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-050485"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2025-04-03T23:59:59+00:00"
generated_at: "2026-05-23T22:43:41.587220+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Tivic Health exercises option for Neutropenia license; accelerates $500K milestone

## Summary
- Exercised Exclusive Option on March 28, 2025 to license Neutropenia indication of Entolimod from Statera.
- Accelerated first milestone payment of $500,000 for IND and Phase 2 study for Neutropenia.
- Issued 55,704 common shares and 131.1267 Series A Preferred shares to Statera and Avenue as consideration.
- Obligated to develop Neutropenia indication at own cost and pay future milestones up to $2.75M for this indication.

## SEC filing metadata
- accession: 0000950170-25-050485
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2025-04-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/0000950170-25-050485-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000095017025050485/tivc-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-050485
- JSON: https://secwatch.observer/filing/0000950170-25-050485.json
- Plain text: https://secwatch.observer/filing/0000950170-25-050485.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.